Breast Ductal Carcinoma in Situ Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting breast ductal carcinoma in situ clinical trials across 2 countries. Studies span Not Applicable, Phase 2, Phase 1. Top locations include Kansas City, Kansas, United States, Houston, Texas, United States, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Breast Ductal Carcinoma in Situ Trials at a Glance

11 actively recruiting trials for breast ductal carcinoma in situ are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Not Applicable with 5 trials, with the heaviest enrollment activity in Kansas City, Houston, and Ann Arbor. Lead sponsors running breast ductal carcinoma in situ studies include National Cancer Institute (NCI), Thomas Jefferson University, and Mayo Clinic.

Browse breast ductal carcinoma in situ trials by phase

Treatments under study

About Breast Ductal Carcinoma in Situ Clinical Trials

Looking for clinical trials for Breast Ductal Carcinoma in Situ? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Breast Ductal Carcinoma in Situ trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Breast Ductal Carcinoma in Situ clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Not Applicable

A Novel Fluorescent Ductal Needle for Localization and Sampling of Micro Lesions in Breast Ducts

Mammary TumorNipple DischargeBreast Ductal Carcinoma in Situ
The Fourth Affiliated Hospital of China Medical University300 enrolled1 locationNCT07339306
Recruiting
Phase 2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)66 enrolled3 locationsNCT06195306
Recruiting
Phase 2

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)80 enrolled4 locationsNCT05941520
Recruiting
Phase 2

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast CarcinomaEstrogen Receptor-Positive Breast CarcinomaBreast Ductal Carcinoma in Situ+3 more
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Invasive Breast CarcinomaBreast Ductal Carcinoma in SituHereditary Breast Carcinoma+1 more
M.D. Anderson Cancer Center600 enrolled4 locationsNCT04169542
Recruiting
Phase 2

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Estrogen Receptor-Positive Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8+5 more
City of Hope Medical Center36 enrolled1 locationNCT06538389
Recruiting
Phase 1

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Breast Ductal Carcinoma in Situ
Mayo Clinic43 enrolled2 locationsNCT04144023
Recruiting
Not Applicable

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Breast CarcinomaBreast Ductal Carcinoma in Situ
Roswell Park Cancer Institute126 enrolled1 locationNCT06350500
Recruiting
Not Applicable

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Anatomic Stage 0 Breast Cancer AJCC v8Triple-Negative Breast CarcinomaInvasive Breast Carcinoma+4 more
Thomas Jefferson University80 enrolled1 locationNCT04959474
Recruiting
Not Applicable

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Malignant Solid NeoplasmBreast Ductal Carcinoma in SituHematopoietic and Lymphoid System Neoplasm+3 more
OHSU Knight Cancer Institute27,500 enrolled2 locationsNCT04494945
Recruiting
Not Applicable

Neoadjuvant Breast Cancer Time Restricted Eating

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+4 more
Thomas Jefferson University55 enrolled1 locationNCT05327608